Articles by Jan Berger, MD, MJ
Understanding and Improving Value Frameworks With Real-World Patient Outcomes
ByAnupam B. Jena, MD, PhD,Jacquelyn W. Chou, MPP, MPL,Lara Yoon, MPH,Wade M. Aubry, MD,Jan Berger, MD, MJ,Wayne Burton, MD,A. Mark Fendrick, MD,Donna M. Fick, RN, PhD,David Franklin, BA,Rebecca Killion, MA,Darius N. Lakdawalla, PhD,Peter J. Neumann, ScD,Kavita Patel, MD, MSHS,John Yee, MD, MPH,Brian Sakurada, PharmD,Kristina Yu-Isenberg, PhD, MPH, RPh New value frameworks should incorporate real-world evidence that reflects patient treatment behavior, adherence to medication, and equity concerns arising from disparities in care.
How Drug Life-Cycle Management Patent Strategies May Impact Formulary Management
ByJan Berger, MD, MJ,Jeffrey D. Dunn, PharmD, MBA,Margaret M. Johnson, BS, RPh,Kurt R. Karst, JD,W. Chad Shear, JD Participating Faculty: Research to Real World Application: Experts Weigh In on the Underuse of Anticoagulants
ByJan Berger, MD, MJ,Donald C. Balfour III, MD, FACP,Joseph E. Biskupiak, PhD, MBA,Jeffrey D. Dunn, PharmD, MBA,Dennis B. Liotta, MD, MBA,Geno J. Merli, MD, FACP, FHM, FSVM,Edmund J. Pezalla, MD, Research to Real-World Application: Experts Weigh In on the Underuse of Anticoagulants
ByJan Berger, MD, MJ,Donald C. Balfour III, MD, FACP,Joseph E. Biskupiak, PhD, MBA,Jeffrey D. Dunn, PharmD, MBA,Dennis B. Liotta, MD, MBA,Geno J. Merli, MD, FACP, FHM, FSVM,Edmund J. Pezalla, MD, This article is the first in a 2-part series that summarizes the proceedings from a roundtable
meeting that was conducted to discuss real-world considerations in nonvalvular
atrial fibrillation and venous thromboembolism.
Increasing Preventive Health Services via Tailored Health Communications
ByKathleen T. Durant, PhD,Jack Newsom, ScD,Elizabeth Rubin, MPA,Jan Berger, MD, MJ,Glenn Pomerantz, MD The authors describe and apply a methodology for defining tailored health communications in order to increase the number of completed colorectal cancer screenings.
Challenges in Diabetes: How to Focus on Individuals, Improve Health of Populations
ByPanel discussion with Josh Benner, PharmD, ScD,Maria Lopes, MD, MS,Nadia S. Islam, PhD,Amy Tenderich,Jan Berger, MD, MJ During the first panel discussion at PCDC 2014, "Addressing Challenges in Diabetes," the panelists talked about individualizing patient care.
Moving beyond the topic, Companion Diagnostics in Targeted Treatment, the panel took on the unregulated nature of testing in the wake of the June 2013 US Supreme Court ruling against Myriad Genetics, which ended the company's BRCA testing monopoly.
Dr Klein moderates this discussion, including co-editor in chief of The American Journal of Pharmacy Benefits Dr Jan Berger. The panel addresses a variety of topics as they relate to companion diagnostics in targeted treatments. Panelists respond to issues such as who should take responsibility in genetic counseling to ensure that patients have the best experience possible-whether it be in person or telephonic. Other topics covered in this discussion include appropriate consumerism in this space, the employer's role in genetic counseling, and how medical professionals are being trained or educated about these processes.